Bringing hope and life-changing therapies to patients & their families
We develop therapies for patients with rare diseases
Our Phase 3 PolarisDMD clinical trial with edasalonexent in muscular dystrophy is ongoing.
September 23, 2020: Catabasis Pharmaceuticals to Present During the Virtual 25th International Congress of the World Muscle Society
September 21, 2020: Catabasis Pharmaceuticals Names Noah Clauser Chief Financial Officer
September 8, 2020: Catabasis Pharmaceuticals to Present at Upcoming Virtual Investor Conferences
We are honored and proud to be members of the Duchenne muscular dystrophy (DMD) community – one that is built on strength and determination.
A potential foundational therapy aimed at improving the lives of all affected by Duchenne.
Join Our Team